Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 May 2;115(5):905-10.
doi: 10.1160/TH15-11-0882. Epub 2016 Feb 18.

Vorapaxar and diplopia: Possible off-target PAR-receptor mismodulation

Victor L Serebruany  1 , Seth D Fortmann, Sunil V Rao, Jean-Francois Tanguay, Marie Lordkipanidze, Daniel F Hanley, Mehmet Can, Moo Hyun Kim, Thomas A Marciniak
Affiliations
Review

Vorapaxar and diplopia: Possible off-target PAR-receptor mismodulation

Victor L Serebruany et al. Thromb Haemost. .

Abstract

Vorapaxar, a novel antiplatelet thrombin PAR-1 inhibitor, has been evaluated in the successful TRA2P trial and the failed TRACER trial. The drug is currently approved for post myocardial infarction and peripheral artery disease indications with concomitant use of clopidogrel and/or aspirin. The FDA ruled that the vorapaxar safety profile is acceptable. However, both trials revealed excess diplopia (double vision) usually reversible after vorapaxar. The diplopia risk appears to be small (about 1 extra case per 1,000 treated subjects), but real. Overall, there were 10 placebo and 34 vorapaxar diplopia cases (p=0.018) consistent for TRACER (2 vs 13 cases; p=0.010) and for TRA2P (8 vs 21 cases; p=0.018). Hence, we review the FDA-confirmed evidence and discuss potential causes and implications of such a surprising adverse association, which may be related to off-target PAR receptor mismodulation in the eye.

Keywords: PAR receptor; Vorapaxar; adverse events; clinical trials; diplopia; safety.

PubMed Disclaimer

Comment in

MeSH terms